Cargando…

Determination of a radotinib dosage regimen based on dose–response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia

Radotinib is a second‐generation BCR‐ABL1 tyrosine kinase inhibitor approved for the treatment of chronic myeloid leukemia in chronic phase (CP‐CML). Here, using the data from a Phase 3 study conducted in patients with newly diagnosed CP‐CML, the dose–efficacy as well as dose–safety relationship ana...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noh, Hayeon, Jung, Su Young, Kwak, Jae‐Yong, Kim, Sung‐Hyun, Oh, Suk Joong, Zang, Dae Young, Lee, Suhyun, Park, Hye Lin, Jo, Dae Jin, Shin, Jae Soo, Do, Young Rok, Kim, Dong‐Wook, Lee, Jangik I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943471/ https://www.ncbi.nlm.nih.gov/pubmed/29577681 http://dx.doi.org/10.1002/cam4.1436

Ejemplares similares

Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)
por: Do, Young Rok, et al.
Publicado: (2020)

Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
por: Heo, Sook-Kyoung, et al.
Publicado: (2020)

BCR‐ABL1 transcript levels at 4 weeks have prognostic significance for time‐specific responses and for predicting survival in chronic‐phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors
por: Song, Hye‐young, et al.
Publicado: (2018)

Radotinib Induces Apoptosis of CD11b(+) Cells Differentiated from Acute Myeloid Leukemia Cells
por: Heo, Sook-Kyoung, et al.
Publicado: (2015)

Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death
por: Heo, Sook-Kyoung, et al.
Publicado: (2017)

Author Correction: Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death
por: Heo, Sook-Kyoung, et al.
Publicado: (2021)

Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation
por: Kim, Kyung Eun, et al.
Publicado: (2018)

Radotinib Decreases Prion Propagation and Prolongs Survival Times in Models of Prion Disease
por: Choi, Yeong-Gon, et al.
Publicado: (2023)

Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling
por: Heo, Sook-Kyoung, et al.
Publicado: (2022)

The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson’s disease mouse model
por: Lee, Saebom, et al.
Publicado: (2018)

The c-Abl inhibitor, radotinib induces apoptosis in multiple myeloma cells via mitochondrial-dependent pathway
por: Heo, Sook-Kyoung, et al.
Publicado: (2021)

Pharmacokinetics of Doripenem in Healthy Koreans and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients With Normal and Enhanced Renal Function
por: Kim, So Won, et al.
Publicado: (2018)

Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults
por: Yoo, Kwai Han, et al.
Publicado: (2020)

Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis
por: Jung, Su Young, et al.
Publicado: (2017)

Radotinib attenuates TGFβ -mediated pulmonary fibrosis in vitro and in vivo: exploring the potential of drug repurposing
por: Baek, Suji, et al.
Publicado: (2022)

Development and validation of analytical method for the determination of radotinib in human plasma using liquid chromatography-tandem mass spectrometry
por: Seo, Hyo-Bum, et al.
Publicado: (2017)

A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis
por: Jung, Jin Ah, et al.
Publicado: (2015)

A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome‐positive chronic myeloid leukemia in chronic phase: ENESTKorea
por: Shin, Junghoon, et al.
Publicado: (2018)

Radotinib is an Effective Inhibitor of Native and Kinase Domain-Mutant BCR-ABL1
por: Zabriskie, Matthew S., et al.
Publicado: (2015)

Application of montmorillonite in bentonite as a pharmaceutical excipient in drug delivery systems
por: Park, Ju-Hwan, et al.
Publicado: (2016)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease
por: Yun, Ji Young, et al.
Publicado: (2017)

Triage of patients with AUS/FLUS on thyroid cytopathology: effectiveness of the multimodal diagnostic techniques
por: Kim, Tae Hyuk, et al.
Publicado: (2016)

Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma
por: Noh, Byeong-Joo, et al.
Publicado: (2020)

The risk of early mortality in elderly patients with newly diagnosed acute myeloid leukemia
por: Liu, Chia‐Jen, et al.
Publicado: (2020)

Improved survival outcomes and restoration of graft‐vs‐leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia
por: Cho, Byung‐Sik, et al.
Publicado: (2019)

Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen
por: Kim, Su-In, et al.
Publicado: (2022)

Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: a retrospective analysis
por: Yi, Hyeon Gyu, et al.
Publicado: (2014)

Lipocalin 2 potentially contributes to tumorigenesis from colitis via IL-6/STAT3/NF-κB signaling pathway
por: Kim, Se Lim, et al.
Publicado: (2022)

Change of right ventricular systolic pressure can indicate dasatinib‐induced pulmonary arterial hypertension in chronic myeloid leukemia
por: Lee, Sung‐Eun, et al.
Publicado: (2021)

Comparison of 7- and 14-Day Eradication Therapy for Helicobacter pylori with First- and Second-Line Regimen: Randomized Clinical Trial
por: Kim, Tae Ho, et al.
Publicado: (2020)

Clathrin‐mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild‐type EGFR non‐small cell lung cancer
por: Kim, Boyeon, et al.
Publicado: (2020)

Bufalin down-regulates Axl expression to inhibit cell proliferation and induce apoptosis in non-small-cell lung cancer cells
por: Kim, Nam-Yi, et al.
Publicado: (2020)

Lung cancer probability and clinical outcomes of baseline and new subsolid nodules detected on low-dose CT screening
por: Kim, Yeon Wook, et al.
Publicado: (2021)

Shikonin inhibits proliferation of melanoma cells by MAPK pathway-mediated induction of apoptosis
por: Lee, Jae Han, et al.
Publicado: (2021)

Differences in diagnosis, treatment, and survival rate of acute myeloid leukemia with or without disabilities: A national cohort study in the Republic of Korea
por: Kwon, Jihyun, et al.
Publicado: (2020)

Survival and clinical prognostic factors in metastatic non‐clear cell renal cell carcinoma treated with targeted therapy: A multi‐institutional, retrospective study using the Korean metastatic renal cell carcinoma registry
por: Kim, Jung Kwon, et al.
Publicado: (2019)

Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced‐stage ovarian cancer
por: Lee, Yong Jae, et al.
Publicado: (2019)

Immunosuppressive role of CD11b(+)CD33(+)HLA‐DR(−) myeloid‐derived suppressor cells‐like blast subpopulation in acute myeloid leukemia
por: Hyun, Shin Young, et al.
Publicado: (2020)

Patient-specific molecular response dynamics can predict the possibility of relapse during the second treatment-free remission attempt in chronic myelogenous leukemia
por: Kim, Eunjung, et al.
Publicado: (2022)

LncRNA SRA mediates cell migration, invasion, and progression of ovarian cancer via NOTCH signaling and epithelial–mesenchymal transition
por: Kim, Lee Kyung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tpnge1ooo44vn6f77g35mbj8go